NGN-401 Gene Therapy Shows Durable Phase 1/2 Gains in Rett Syndrome; Embolden Topline Data Due 2H 2027
NGNE has more than doubled off its 52-week low of $14.65 on elevated volume (3.1× avg).
Summary
Neurogene reported highly positive long-term Phase 1/2 clinical data for its NGN-401 gene therapy in Rett syndrome. The study showed 47 developmental milestones gained across 10 participants, with improvements proving durable for up to 30 months. This news follows an 8-K filed minutes earlier, detailing these significant clinical results. Strong Phase 1/2 data substantially de-risks the NGN-401 program and supports its potential path to market, with durable efficacy being a critical factor for gene therapies. Topline data from the Embolden registrational trial is expected in the second half of 2027.
At the time of this announcement, NGNE was trading at $33.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $506.1M. The 52-week trading range was $14.65 to $37.27. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.